Cancer research
Researchers at the Dana-Farber Cancer Institute have explored the potential of innate immune cells, including natural killer cells, macrophages, and gamma delta T cells, in cancer immunotherapy. These cells possess attributes that make them suitable candidates for cancer treatment, such as inherent antitumor activity, rapid immune responses, and favorable safety
Cancer
Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique to cancer cells. According to researchers from Duke University, these neoantigens serve as highly specific targets for personalized therapies, promising more effective and
Cancer
A groundbreaking study from Rostock University Medical Center in Germany has shed new light on the relationship between cancer drivers and immune response. Researcher Rosaely Casalegno Garduno and colleagues have identified cancer heterogeneity as a significant challenge to immunotherapy, highlighting the need for improved biomarkers to predict treatment efficacy. The
Cancer
Researchers at Inner Mongolia University have published a new study highlighting the potential of gd T cells, a type of specialized T cell, in cancer treatment. The study focuses on the unique properties of gd T cells, including their ability to directly recognize and bind antigenic molecules without the need
Cancer
A recent study published in the journal Current Oncology has shed light on the pathogenesis, diagnosis, and management of Cytokine Release Syndrome (CRS), a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs). According to the research, CRS often mimics infectious and inflammatory conditions,
Cancer
A systematic review and meta-analysis of artificial intelligence (AI) networks has shown promising potential in predicting immunotherapy outcomes for gastrointestinal cancers based on genetic mutation features. The study, published in BMC Gastroenterology, analyzed 45 studies involving 14,047 participants and found that AI models were able to predict immunotherapy responses
Child health
Researchers at the University of Virginia Health have successfully conducted a real-world study on peanut oral immunotherapy in children younger than 3, showing that the approach is safe and effective at desensitizing children to peanuts. The study found that 27 out of 30 children who completed the trial were able
Allergens
Researchers have made significant progress in developing a novel treatment for peanut allergy, using epicutaneous immunotherapy (EPIT). This approach promotes tolerance to food allergens by harnessing the power of the cutaneous immune system. The University of North Carolina's research team, led by A. Wesley Burks, has been working
Immunotherapy
Researchers in Australia have found that exposure to polluted air in early childhood increases the risk of developing a peanut allergy. The study, which tracked nearly 5,300 children in Melbourne, found that as rates of air pollution rose, so did the odds of developing a peanut allergy. The connection
Immunotherapy
Researchers at the Curie Institute in Paris, France have conducted a retrospective analysis of a large database of lung cancer patients to investigate the impact of KRAS mutations on disease phenotype and survival outcomes. The study found that patients with KRAS mutations were more likely to be smokers and had
Immunotherapy
New research has shown that Ecklonia cava, a type of seaweed rich in antioxidants, can help prevent Parkinson's disease, among other health benefits. This nutrient-dense seaweed is also beneficial for boosting the immune system, lowering cholesterol and blood pressure, and providing essential vitamins and minerals. To harness its
Allergens
Australian clinical-stage biotechnology company, Prota Therapeutics, has announced the publication of a study in the journal Allergy, which compares remission and desensitization endpoints following food allergen oral immunotherapy (OIT). The Phase 2b follow-on study, PPOIT-003LT, reports 2-year post-treatment outcomes for Prota's remission-inducing high-dose peanut oral immunotherapies, PRT120 and
